Monthly Archives: November 2016
Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency
Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) suppress gastric acid production, which may inhibit iron absorption. However, little data exist regarding whether these medications increase the risk of clinical iron deficiency. Continue reading
A Curmudgeon Reflects on Half a Century of Gastrointestinal Pathology
As a surgical pathologist, I have concentrated on the study and diagnosis of gastrointestinal (GI) diseases for 50 years. During my training, there were only a few pathologists worldwide who were known for their expertise in GI diseases, including Basi… Continue reading
A Curmudgeon Reflects on Half a Century of Gastrointestinal Pathology
As a surgical pathologist, I have concentrated on the study and diagnosis of gastrointestinal (GI) diseases for 50 years. During my training, there were only a few pathologists worldwide who were known for their expertise in GI diseases, including Basi… Continue reading
Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor−Mediated Destruction of Intestinal Epithelial Cells
Tumor necrosis factor (TNF) is a cytokine that promotes inflammation and contributes to pathogenesis of inflammatory bowel diseases. Unlike other cells and tissues, intestinal epithelial cells undergo rapid cell death upon exposure to TNF, by unclear m… Continue reading
Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor−Mediated Destruction of Intestinal Epithelial Cells
Tumor necrosis factor (TNF) is a cytokine that promotes inflammation and contributes to pathogenesis of inflammatory bowel diseases. Unlike other cells and tissues, intestinal epithelial cells undergo rapid cell death upon exposure to TNF, by unclear m… Continue reading
Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis
Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label use of corticosteroids not optimized for esophageal delivery. We performed a randomized, controlled phase 2 trial to assess the ability of budesonide oral suspension (BOS… Continue reading
Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis
Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label use of corticosteroids not optimized for esophageal delivery. We performed a randomized, controlled phase 2 trial to assess the ability of budesonide oral suspension (BOS… Continue reading
Endoscopic Findings in Eosinophilic Esophagitis and Esophageal Distensibility: A Proxy for Transmural Modeling?
Chen JW, Pandolfino JE, Lin Z, et al. Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis. Endoscopy 2016;48:1–8. Continue reading
Endoscopic Findings in Eosinophilic Esophagitis and Esophageal Distensibility: A Proxy for Transmural Modeling?
Chen JW, Pandolfino JE, Lin Z, et al. Severity of endoscopically identified esophageal rings correlates with reduced esophageal distensibility in eosinophilic esophagitis. Endoscopy 2016;48:1–8. Continue reading
Genetic Optimization of Liver Cancer Therapy: A Patient-Derived Primary Cancer Cell-Based Model
Hepatocellular carcinoma (HCC) is characterized by distinct interpatient tumor heterogeneity,1 and patients often respond in markedly different ways to treatment or show drug resistance. This complexity is further emphasized by intratumor heterogeneity… Continue reading